Abstract

Human pluripotent stem cells (PSCs) offer a scalable alternative to primary and transformed human tissue. PSCs include human embryonic stem cells, derived from the inner cell mass of blastocysts unsuitable for human implantation; and induced PSCs, generated by the reprogramming of somatic cells. Both cell types display the ability to self-renew and retain pluripotency, promising an unlimited supply of human somatic cells for biomedical application. A distinct advantage of using PSCs is the ability to select for genetic background, promising personalized modelling of human biology ‘in a dish’ or immune-matched cell-based therapies for the clinic. This special issue will guide the reader through stem cell self-renewal, pluripotency and differentiation. The first articles focus on improving cell fidelity, understanding the innate immune system and the importance of materials chemistry, biofabrication and bioengineering. These are followed by articles that focus on industrial application, commercialization and label-free assessment of tissue formation. The special issue concludes with an article discussing human liver cell-based therapies past, present and future.This article is part of the theme issue ‘Designer human tissue: coming to a lab near you’.

Highlights

  • Cite this article: Hay DC, O’Farrelly C. 2018 Designer human tissue: coming to a lab near you

  • Clinical trials will commence using pluripotent stem cells (PSCs)-derived dopaminergic neurons to treat Parkinson’s disease. The output from those well-controlled clinical trials will determine the suitability of PSCs for developing pioneering cell-based therapies

  • Both types of PSCs are renewable, a distinct advantage of using iPSC-based systems is the ability to select for genetic background, promising personalized modelling of human biology ‘in a dish’ and/or immune-matched cell-based therapies for the clinic

Read more

Summary

Introduction

Cite this article: Hay DC, O’Farrelly C. 2018 Designer human tissue: coming to a lab near you. Human pluripotent stem cells (PSCs) offer a scalable alternative to primary and transformed human tissue. A distinct advantage of using PSCs is the ability to select for genetic background, promising personalized modelling of human biology ‘in a dish’ or immune-matched cell-based therapies for the clinic. The special issue concludes with an article discussing human liver cell-based therapies past, present and future.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call